



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: November 30, 2005 Signature: *Marian L. Christopher*  
(Marian L. Christopher)

Docket No.: 532512000401  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:

Gregory M. LANZA et al.

Application No.: 10/620,725

Filed: July 15, 2003

For: LIGAND-TARGETED EMULSIONS  
CARRYING BIOACTIVE AGENTS

Confirmation No.: 1157

Art Unit: 1615

Examiner: Gollamudi S. Kishore, Ph.D.

**AMENDMENT UNDER 37 C.F.R. § 1.116**

MS AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to an Office Action herein, mailed 1 August 2005, time for response to which was set to expire 1 November 2005. A petition for an extension of time of one (1) month until 1 December 2005 is attached hereto, along with the required fee. The pending claims were rejected and the rejection was made final.

Applicants appreciate the thoughtfulness and consideration extended their undersigned representative at an interview concerning the issues outstanding in this case conducted on 9 November. The discussion was most helpful, and the following remarks take account of this discussion.

Careful consideration has been given to the grounds for rejection, as well as the discussion as the interview and the following amendment and remarks are offered in response.

Reconsideration and entry of the amendment are respectfully requested.

Attached for the convenience of the Office is a copy of the Opinion in *Glaxo, Inc. v. Novopharm, Ltd.*, 52 F3d 1043, 34 USPQ2d 1565 (Fed. Cir. 1995).